Chemistry:CYB003

From HandWiki

CYB003, or CYB-003, also known as deuterated psilocybin analogue, is a serotonergic psychedelic related to psilocybin which is under development for the treatment of major depressive disorder, alcoholism, and other psychiatric disorders.[1][2][3][4][5][6][7] It is taken by mouth.[1]

It is a tryptamine derivative and is a deuterated analogue of psilocybin and psilocin.[1][3][4][6] The pharmacodynamic profile of CYB003, including its interactions with serotonin receptors and its effects in animals, is similar to that of psilocin.[6] As with psilocin, CYB003 is a potent agonist of the serotonin 5-HT2A receptor and produces psychedelic-like effects in animals.[6] However, it was developed to have improved pharmacokinetic properties compared to psilocybin, including reduced variability in circulating levels, a faster onset of action, and a shorter duration.[7]

In 2024, CYB003 received a breakthrough therapy designation from the U.S. FDA[8] and was in phase 3 clinical trials for major depressive disorder and is in the preclinical stage of development for alcoholism and other psychiatric disorders.[1][2][9] Two phase 3 clinical trials for major depressive disorder are being initiated in November 2024 and February 2025.[1][2][9] The drug is under development by Cybin.[1][2][9] The chemical structure of CYB003 has not yet been disclosed.[4][3] However, Cybin patented deuterated tryptamines including the dideuterated psilocin analogue PI-α,α-d2 (psilocin dideuterated at the α carbon) in 2023.[10] Other related drugs include the deuterated tryptamine CYB004, the deuterated phenethylamine CYB005, and the phenethylamine CYB210010.[3][11]

An INN of deupsilocin for a deuterated form of psilocin called d10-psilocin with CAS number 1435934-64-7 was proposed in 2023 and recommended in 2024.[12][13][14] This deuterated analogue of psilocin was patented in 2021 by Lennham Pharmaceuticals.[14]

See also

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 "CYB 003". 4 October 2024. https://adisinsight.springer.com/drugs/800062409. 
  2. ↑ 2.0 2.1 2.2 2.3 "Delving into the Latest Updates on CYB-003 with Synapse". 12 October 2024. https://synapse.patsnap.com/drug/dcb535376933495783bad0ae5504a571. 
  3. ↑ 3.0 3.1 3.2 3.3 "Key Characteristics and Development of Psychoceuticals: A Review". Int J Mol Sci 23 (24). December 2022. doi:10.3390/ijms232415777. PMID 36555419. 
  4. ↑ 4.0 4.1 4.2 "Deuterium in drug discovery: progress, opportunities and challenges". Nat Rev Drug Discov 22 (7): 562–584. July 2023. doi:10.1038/s41573-023-00703-8. PMID 37277503. 
  5. ↑ "Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders". Drug Discov Today 28 (12). December 2023. doi:10.1016/j.drudis.2023.103818. PMID 37925136. 
  6. ↑ 6.0 6.1 6.2 6.3 "ACNP 61st Annual Meeting: Poster Abstracts P271-P540: P361. In Vitro and In Vivo Profile of CYB003: A Novel, Deuterated Psilocybin Analog for the Potential Treatment of Major Depressive Disorder". Neuropsychopharmacology 47 (Suppl 1): 220–370 (271). December 2022. doi:10.1038/s41386-022-01485-0. PMID 36456694. PMC 9714399. https://cybin.com/wp-content/uploads/2023/09/ACNP_2022_CYB003_Poster-1.pdf. 
  7. ↑ 7.0 7.1 "ACNP 61st Annual Meeting: Poster Abstracts P271-P540: P362. Pharmacokinetic Profile of CYB003: A Novel, Deuterated Psilocybin Analog for the Potential Treatment of Major Depressive Disorder". Neuropsychopharmacology 47 (Suppl 1): 220–370 (271–272). December 2022. doi:10.1038/s41386-022-01485-0. PMID 36456694. PMC 9714399. https://cybin.com/wp-content/uploads/2023/09/ACNP-2022-CYB003-Poster-2.pdf. 
  8. ↑ Jenkins, Cassandra (19 March 2024). "FDA grants breakthrough designation to psilocybin analog for major depressive disorder". https://www.healio.com/news/psychiatry/20240319/fda-grants-breakthrough-designation-to-psilocybin-analog-for-major-depressive-disorder. 
  9. ↑ 9.0 9.1 9.2 Kuntz, Leah (10 February 2025). "CYB003 for the Adjunctive Treatment of Major Depressive Disorder". https://www.psychiatrictimes.com/view/cyb003-for-the-adjunctive-treatment-of-major-depressive-disorder. 
  10. ↑ "Deuterated tryptamine derivatives and methods of use". 17 July 2023. https://patents.google.com/patent/US20230357147A1/en. "Binding affinity (Ki) and functional potency (EC50) values of PI and PI-α-d2 are summarized in Table 1. Deuteration was found to have little effect on the affinity and function at key receptor targets. [...] TABLE 1: PI and PI-α,α-d2 Affinities and Functions at Target Serotonin Receptors [...]" 
  11. ↑ "Next-generation psychedelics: should new agents skip the trip?". Nat Biotechnol 42 (6): 827–830. June 2024. doi:10.1038/s41587-024-02285-1. PMID 38831049. 
  12. ↑ deupsilocinum deupsilocin 3-[2-{di[(2H3)methyl]amino}(2H4)ethyl]-1H-indol-4-ol psychodysleptic [...] C12H62H10N2O 1435934-64-7 https://www.who.int/docs/default-source/international-nonproprietary-names-(inn)/pl129.pdf#page=35
  13. ↑ deupsilocinum deupsilocin 3-[2-{di[(2H3)methyl]amino}(2H4)ethyl]-1H-indol-4-ol [...] C12H62H10N2O https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-%28inn%29/rl91.pdf
  14. ↑ 14.0 14.1 Bradford Sippy, "Deuterated Derivatives of Psilocybin and Uses Thereof", US patent 11000534, published 11 May 2021, issued 11 May 2021, assigned to Lennham Pharmaceuticals, Inc.

Template:Psychedelics



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:CYB003&oldid=4038467"